Kholes

ARMGO Pharma is developing a novel drug based on a new strategy for treating muscle weakness and degeneration in Duchenne MD, Becker MD and potentially other muscle disorders

posted on April 17, 2013 - 2:30am
MDA has awarded $1 million to biopharmaceutical company ARMGO Pharma for development of a new strategy for treating Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD).

FDA has asked Sarepta Therapeutics for additional information about dystrophin production and safety before it will consider accepting an application for accelerated approval of its exon-skipping drug

posted on April 15, 2013 - 6:27pm
The U.S. Food and Drug Administration (FDA) has said it will consider accepting an application for accelerated approval for eteplirsen, an experimental drug for Duchenne muscular dystrophy (DMD), after it reviews additional data from clinical trials of the drug.